301 Using PK/PD/efficacy modeling to predict potential of AZD9291 to target brain metastases from advanced NSCLC with EGFR sensitizing mutations (EGFRm+)
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.